CI

At a glance

ClinicalIndex Comparison Record
N/ANot Yet Recruiting· 3,000 target
Drug / intervention
Tenecteplasedrug
Likely dose
Tenecteplase 0.25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07536165
NCT07536165N/ANot Yet Recruiting

Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke (EXTEND-TNK Registry)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·observational·Posted Apr 17, 2026·Updated Apr 17, 2026

In Brief

An observational study evaluating Tenecteplase for Stroke and Acute Ischemic Stroke. Not yet recruiting, targeting 3,000 participants across 2 sites.

Detailed Summary

The EXTEND-TNK Registry is a prospective, multicenter, observational cohort study designed to evaluate the effectiveness and safety of intravenous tenecteplase administered beyond 4.5 hours after last known well in patients with acute ischemic stroke (AIS) in routine clinical practice across China.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ANot Yet Recruiting
2027202820292030
First PostedApr 17, 2026
Enrollment StartApr 1, 2026
Primary CompletionDec 1, 2028
Study CompletionDec 1, 2029
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 2 months agoPrimary completion in 2.4 years

Interventions

Tenecteplasedrug

Intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) administered as a single IV bolus over 5-10 seconds. In this observational cohort, tenecteplase is the only thrombolytic agent included and there is no active comparator.